Since the approval of pembrolizumab in 2014 for the treatment of advanced melanoma, PD-1/PD-L1 ICIs have revolutionized treatment modes ranging from Hodgkin lymphoma to advanced endometrial carcinoma [30]. The gene discussed is CD274; the disease is Hodgkins lymphoma.